Stayble Therapeutics AB (OSTO:STABL) Net Margin %: 0.00% (As of Mar. 2026)


OSTO:STABL Stayble Therapeutics AB OSTO:STABL
28 GF Score
Price kr0.21
! 1 Warning Sign
View Full Analysis

What is Stayble Therapeutics AB Net Margin %?

Stayble Therapeutics AB OSTO:STABL 28 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates OSTO:STABL with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 947 Biotechnology companies, Stayble Therapeutics AB ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Stayble Therapeutics AB's Net Income for the three months ended in Mar. 2026 was kr-5.86 Mil. Stayble Therapeutics AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, Stayble Therapeutics AB's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Stayble Therapeutics AB's Net Margin % or its related term are showing as below:


OSTO:STABL's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Stayble Therapeutics AB  (OSTO:STABL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Stayble Therapeutics AB Net Margin % Related Terms

Stayble Therapeutics AB Net Margin % Historical Data

* Premium members only.

The historical data trend for Stayble Therapeutics AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stayble Therapeutics AB Net Margin % Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Stayble Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OSTO:STABL vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Stayble Therapeutics AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Net Margin % falls into.


OSTO:STABL
28GF Score
Stayble Therapeutics AB OSTO:STABL
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stayble Therapeutics AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Stayble Therapeutics AB's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-6.928/0
= %

Stayble Therapeutics AB's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.862/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Stayble Therapeutics AB (OSTO:STABL) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Stayble Therapeutics AB and its competitors. According to the industry distribution chart, Stayble Therapeutics AB ranks #999999 out of 947 companies in the Biotechnology industry.
Is Stayble Therapeutics AB's Net Margin % too high?
Stayble Therapeutics AB's current Net Margin % is 0.00%. Based on the distribution chart, Stayble Therapeutics AB ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stayble Therapeutics AB ranks #999999 out of 947 companies for Net Margin %. This places Stayble Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Stayble Therapeutics AB and its competitors. Stayble Therapeutics AB's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (OSTO:STABL) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Stayble Therapeutics AB (OSTO:STABL), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stayble Therapeutics AB Business Description

Other Exchanges 4K4:Germany
Address Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score

Get the complete analysis for OSTO:STABL

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.21
Price